<DOC>
	<DOCNO>NCT01566721</DOCNO>
	<brief_summary>This multicenter , two-cohort , non-randomized , open-label study evaluate safety tolerability assisted- self-administered subcutaneous Herceptin ( trastuzumab ) adjuvant therapy patient early HER2-positive breast cancer whose tumour excise . Patients receive Herceptin 600 mg subcutaneously every 3 week 18 cycle , either assist administration use conventional syringe needle ( vial formulation , Cohort A ) assisted- self-administration use single-use injection device ( SID ) select patient ( Cohort B ) . Anticipated time study treatment 1 year .</brief_summary>
	<brief_title>A Safety Tolerability Study Assisted- Self-Administered Subcutaneous Herceptin ( Trastuzumab ) Adjuvant Therapy Patients With Early HER2-Positive Breast Cancer ( SafeHer )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult male female patient , &gt; /= 18 year age Histologically confirm early invasive HER2positive carcinoma breast evidence residual , locally recurrent metastatic disease define clinical stage I IIIC eligible adjuvant treatment trastuzumab Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Screening leave ventricular ejection fraction ( LVEF ) &gt; /= 55 % Previous neoadjuvant adjuvant breast cancer treatment approve investigational antiHER2 agent History malignancy , except curatively treat carcinoma situ cervix basal cell carcinoma patient curatively treated malignancy , breast cancer , diseasefree least 5 year Past history ductal carcinoma situ treat systemic therapy radiation therapy ipsilateral breast invasive cancer subsequently develop Metastatic disease Inadequate bone marrow , hepatic renal function Serious cardiac cardiovascular disease Uncontrolled hypertension , history hypertensive crisis hypertensive encephalopathy History severe allergic immunological reaction , e.g . difficult control asthma Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>